Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Questions With BTK Inhibitors and Anti-CD20 Combos Require Further Study in CLL

April 10th 2020

Farrukh Awan, MD, discusses the rationale for combining BTK inhibitors with CD20-directed monoclonal antibodies in CLL, sequencing challenges, and remaining questions in the chronic lymphocytic leukemia.

Dr. Woyach on the Utility of Time-Limited Therapies in CLL

April 9th 2020

Jennifer Woyach, MD, discusses the utility of time-limited therapies in chronic lymphocytic leukemia.

Dr. Mato on the Efficacy of Fixed-Duration Venetoclax-Based Combo in CLL

April 8th 2020

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Dr. Awan on Future of Combo Regimens in CLL Treatment Paradigm

April 8th 2020

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Acalabrutinib Triplet Impresses in Frontline CLL, Advances to Phase III Study

April 7th 2020

The addition of acalabrutinib (Calquence) to venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia, eliciting deep and durable responses.

Dr. Danilov on Venetoclax Plus BTK Inhibitors in CLL

April 7th 2020

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Dr. Raphael on Addressing the Risk of Tumor Lysis Syndrome in CLL

April 4th 2020

Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.

Dr. Choi on the Utility of Duvelisib in CLL

April 4th 2020

Michael Choi, MD, discusses the utility of duvelisib in chronic lymphocytic leukemia.

Dr. Choi on Impact of Frontline Treatment Decisions on Relapsed/Refractory CLL

April 3rd 2020

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Dr. Awan on Novel Strategies Under Exploration in Relapsed/Refractory CLL

April 2nd 2020

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum

March 20th 2020

Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.

Investigators Pursue Less-Toxic Treatment in Frontline CLL

March 16th 2020

Investigators are evaluating whether the addition of venetoclax to a standard doublet regimen in chronic lymphocytic leukemia can induce responses deep enough to allow patients to not only suspend long-term treatment but also avoid associated toxicity.

Optimizing Frontline Therapy With Cost-Savings Considerations in CLL

March 12th 2020

Matthew S. Davids, MD, MMSc, discusses data that were presented with novel combinations in chronic lymphocytic leukemia at the 2019 ASH Annual Meeting and the importance of conducting cost-effective analyses.

Frontline Venetoclax/Obinutuzumab Approved in Europe in CLL

March 12th 2020

The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Dr. Raphael on the CLARITY Trial in CLL

March 10th 2020

Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).

Dr. Woyach on Treatment Challenges in CLL

March 7th 2020

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.

Dr. Awan on Utilizing Acalabrutinib in CLL

March 6th 2020

Farrukh Awan, MD, discusses the utilization of acalabrutinib in patients with chronic lymphocytic leukemia.

CLL Treatment Paradigm Expands Toward Novel Combo Regimens

March 6th 2020

Bruce G. Raphael, MD, discusses recent pivotal trials in chronic lymphocytic leukemia and the utility of triplet regimens for older patients.

Dr. Choi on Frontline Treatment Considerations in CLL

March 4th 2020

Michael Choi, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Pagel on Time-Limited Therapy in CLL

March 4th 2020

John M. Pagel, MD, PhD, discusses time-limited therapy in chronic lymphocytic leukemia.